RN Mobile Menu

Search form


Physicians Forgo Psoriatic Arthritis Treatment Adjustments

Physicians Forgo Psoriatic Arthritis Treatment Adjustments

Remaining disease activity was present in almost two-thirds of patients with psoriatic arthritis in a recent study when disease activity parameters were scored by the treating rheumatologist.

Although options for treatment changes are available, the researchers found that treatment is not adjusted for a large majority of patients who have residual disease activity.

Treatment options for patients with psoriatic arthritis increased significantly over the past decade, they noted. Leflunomide and tumor necrosis factor (TNF) inhibitors became part of the standard therapeutic arsenal, and several other new treatments—including ustekinumab, apremilast, and secukinumab—became available.

Also, the Tight Control of Psoriatic Arthritis (TICOPA) trial demonstrated that the availability of treatments and the strategy on how to use them determines the clinical outcome. The treat-to-target arm showed significantly better outcomes in peripheral arthritis, skin, and patient reported outcomes than the standard-care arm.

Reports indicate that not many patients are in a minimal disease state in spite of receiving treatment in a clinical practice, the authors stated. Possible reasons for residual disease activity include (1) patients are not responding to all available treatments; (2) comorbidities, adverse effects, and incompliance are resulting in patients’ inability or unwillingness to use available medications; and (3) the currently available treatments are not being used optimally.

The researchers conducted the study to assess current clinical practice on defining residual disease in patients with psoriatic arthritis and making subsequent treatment decisions.

They reported their findings in a recent issue of Arthritis Research & Therapy.

The study

The cross-sectional study scored disease activity and treatment decisions prospectively in 142 consecutive patients with psoriatic arthritis who visited an outpatient clinic for routine follow-up. Disease activity parameters were scored by the patient and the treating rheumatologist. The rheumatologist also registered an opinion on the presence of remaining disease activity in spite of current and subsequent treatment decisions.

The treatment options available in clinical practice during the inclusion period were limited to conventional disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate and leflunomide, and TNF inhibitors. Because ustekinumab became available for use in clinical practice just before the study, this was not a common drug to prescribe at that time.


Following are some of the results:

• Two-thirds of the patients had remaining disease activity according to the treating rheumatologist.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.